Lisata regains China rights to pancreatic cancer drug

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said it has mutually terminated a licensing and collaboration agreement with China's Qilu Pharmaceutical, regaining full rights to its cancer drug candidate certepetide in the Greater China region. The February 2021 agreement granted Qilu exclusive rights to develop and commercialize certepetide in Mainland China, Hong Kong, Macau and Taiwan.

Proactive Investors • Jan 27, 2026

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

Lisata regains full development rights to certepetide in the Greater China Region Lisata regains full development rights to certepetide in the Greater China Region

GlobeNewsWire • Jan 27, 2026

Lisata Therapeutics to be acquired by Kuva Labs in $4-per-share cash deal

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said on Wednesday it has agreed to be acquired by privately held Kuva Labs in a cash deal valuing the clinical-stage drug developer at $4 per share, plus potential contingent payments tied to regulatory and licensing milestones. Under the terms of a binding term sheet, Kuva will launch a tender offer to buy all outstanding Lisata shares for $4 each in cash, with shareholders also eligible to receive up to $2 per share through two non-tradeable contingent value rights, Lisata said.

Proactive Investors • Jan 21, 2026

Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer

Stockholders to also receive two contingent value rights valued at $1 per share, each entitled to be received upon the achievement of certain milestones Offer represents an approximate 85% premium over the most recent closing price of Lisata stock BASKING RIDGE, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has entered into a binding term sheet to be acquired by Kuva Labs, Inc. (“Kuva”), a privately-held company.

GlobeNewsWire • Jan 21, 2026

LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Lisata Therapeutics, Inc. (NASDAQ: LSTA) to Kuva Labs, Inc. for $4.00 per share in cash plus two non-tradeable contingent value rights payable under certain conditions is fair to Lisata shareholders. Halper Sadeh encourages Lisata shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersade.

Business Wire • Jan 21, 2026

Lisata Therapeutics receives 2025 BioTech Breakthrough Award for 'Overall BioPharma Solution of the Year'

Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has won the “Overall BioPharma Solution of the Year” in the fifth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, an independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services throughout the world.  The clinical-stage pharmaceutical company said the award is in recognition of its unique therapeutic approach and focused clinical development plans, designed to produce products to address the unmet medical needs of patients with advanced solid tumors.

Proactive Investors • Nov 6, 2025

Lisata Therapeutics advances certepetide, inks strategic alliances in Q3

Lisata Therapeutics Inc (NASDAQ:LSTA) has reported financial results for the third quarter, highlighting continued clinical progress for its lead investigational therapy, certepetide, and announcing strategic collaborations to expand its development and discovery capabilities. Certepetide, Lisata's proprietary investigational peptide, continues to be studied across multiple solid tumor types in combination with standard anti-cancer therapies.

Proactive Investors • Nov 6, 2025

Lisata Therapeutics, Inc. (LSTA) Q3 2025 Earnings Call Transcript

Lisata Therapeutics, Inc. ( LSTA ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants John Menditto - Vice President of Investor Relations & Corporate Communications David Mazzo - President, CEO & Director James Nisco - Senior VP of Finance, Treasurer, CAO & Principal Financial and Accounting Officer Kristen Buck - Executive VP of R&D and Chief Medical Officer Conference Call Participants Lander Egaña-Gorroño Robert Sassoon - Water Tower Research LLC Peter Enderlin - MAZ Capital Advisors, LLC Brian Kemp Dolliver - Brookline Capital Markets, LLC, Research Division Presentation Operator Welcome to the Lisata Therapeutics Third Quarter 2025 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, Thursday, November 6, 2025.

Seeking Alpha • Nov 7, 2025

Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Data rich period continues to support certepetide's broad applicability and effectiveness Catalent enters into global license agreement for the use of certepetide as part of their SMARTag® Antibody-Drug Conjugate Technology Platform Strategic Alliance formed with GATC Health to exploit their Multiomics Advanced Technology™ artificial intelligence drug discovery platform Cash runway extended into the first quarter of 2027 with no debt Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J.

GlobeNewsWire • Nov 6, 2025

Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year'

BASKING RIDGE, N.J. , Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced it is the recipient of “Overall BioPharma Solution of the Year” in the fifth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.

GlobeNewsWire • Nov 6, 2025